Disparities in OUD treatment: Buprenorphine vs. naltrexone
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
Rare diseases may be individually uncommon, but collectively they affect an estimated 30 million people in the United States. Yet for many patients, the path to diagnosis spans years, sometimes decades. Symptoms appear one at a time. Specialists...
Understanding disparities in opioid use disorder (OUD) treatment Pharmaceutical companies committed...
(Part 1) When clients see real-world data (RWD) in HealthVerity Marketplace, it may appear...
Electronic Health Records (EHR): What they are and how to use them in real-world data Electronic...
Antiretroviral therapy (ART) has transformed outcomes for people living with HIV, especially those...
In this edition of our Ask an Expert series, we turn to Emery Niemiec, Senior Director,...
Mapping food allergy care with omalizumab and real-world data IgE-mediated food allergies (FAs)...
High-risk NMIBC: Disease overview and treatment approach Johnson & Johnson quickly identified and...
Government health agencies are increasingly turning to real-world data (RWD) for public health...
HealthVerity recently introduced HealthVerity Notes, our newest product designed to unlock the...
AI-driven mortality models are supposed to provide accurate, data-backed insights into patient...
When our client, a global pharmaceutical company, set out to better understand long COVID pathways, they had a central question to answer:how much of the long COVID population are we missing if we rely on diagnosis codes alone?